Ziopharm's darinaparsin gets orphan-drug status from the FDA

09/23/2010 | Fox Business

The FDA granted orphan-drug designation to darinaparsin, Ziopharm Oncology's treatment for peripheral T-cell lymphoma. The company plans to launch a Phase I study in late 2011 to test the tolerability of the drug when combined with standard treatment.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC